Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immunovant, Inc. (IMVT : NSDQ)
 
 • Company Description   
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.

Number of Employees: 362

 
 • Price / Volume Information   
Yesterday's Closing Price: $17.50 Daily Weekly Monthly
20 Day Moving Average: 1,109,483 shares
Shares Outstanding: 171.07 (millions)
Market Capitalization: $2,993.71 (millions)
Beta: 0.63
52 Week High: $34.34
52 Week Low: $12.72
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.79% 5.68%
12 Week 15.51% -2.84%
Year To Date -29.35% -33.84%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
320 WEST 37TH STREET
-
NEW YORK,NY 10018
USA
ph: 917-580-3099
fax: -
info@immunovant.com http://www.immunovant.com
 
 • General Corporate Information   
Officers
Eric Venker - Chief Executive Officer
Frank M. Torti - Executive Chairperson
Tiago Girao - Chief Financial Officer
Jacob Bauer - Director
Andrew Fromkin - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45258J102
SIC: 2836
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 171.07
Most Recent Split Date: (:1)
Beta: 0.63
Market Capitalization: $2,993.71 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.90 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.20
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -23.08%
vs. Previous Quarter: 15.79%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -80.60
12/31/24 - -77.94
ROA
06/30/25 - -
03/31/25 - -71.89
12/31/24 - -69.82
Current Ratio
06/30/25 - -
03/31/25 - 11.16
12/31/24 - 6.04
Quick Ratio
06/30/25 - -
03/31/25 - 11.16
12/31/24 - 6.04
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 4.16
12/31/24 - 2.08
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©